High-Risk Acute Myeloid Leukemia Clinical Trials

6 recruiting

Frequently Asked Questions

Common questions about High-Risk Acute Myeloid Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Not Applicable

Clinical Study to Evaluate the Safety and Efficacy of γδ T Cells for the Prevention of Relapse After Allogeneic Transplantation in Patients With High-risk Acute Myeloid Leukemia

High-Risk Acute Myeloid Leukemia
Donghua Zhang40 enrolled1 locationNCT07237230
Recruiting
Not Applicable

Novel Digital Application for Patients With Acute Leukemia

High-Risk Acute Myeloid LeukemiaPrimary Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia
Massachusetts General Hospital200 enrolled3 locationsNCT06472128
Recruiting
Not Applicable

Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)

Acute Myeloid LeukemiaMyelodysplastic SyndromesHigh-Risk Acute Myeloid Leukemia+1 more
First Affiliated Hospital of Zhejiang University138 enrolled1 locationNCT07183878
Recruiting
Not Applicable

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Relapsed Adult AMLHigh-Risk Acute Myeloid LeukemiaPrimary Refractory Acute Myeloid Leukemia
Massachusetts General Hospital2,300 enrolled20 locationsNCT05237258
Recruiting
Phase 1Phase 2

Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT

LeukemiaInborn Errors of MetabolismHLH+11 more
Children's Hospital of Philadelphia100 enrolled1 locationNCT06839456
Recruiting
Phase 2

Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients

High-Risk Acute Myeloid LeukemiaIntermediate Risk Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University60 enrolled1 locationNCT06394011